Aspira Pathlab & Diagnostics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
For the full year, sales was INR 144.57 million compared to INR 195.42 million a year ago. Revenue was INR 147.78 million compared to INR 196.45 million a year ago. Net loss was INR 0.887 million compared to net income of INR 44.59 million a year ago. Basic loss per share from continuing operations was INR 0.09 compared to basic earnings per share from continuing operations of INR 4.33 a year ago. Diluted loss per share from continuing operations was INR 0.09 compared to diluted earnings per share from continuing operations of INR 4.33 a year ago.